Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …

Background In the Step Study, the MRKAd5 HIV-1 gag/pol/nef vaccine did not reduce plasma
viraemia after infection, and HIV-1 incidence was higher in vaccine-treated than in placebo-…

Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we
evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based …

Background In efficacy trials of a tetravalent dengue vaccine (CYD-TDV), excess hospitalizations
for dengue were observed among vaccine recipients 2 to 5 years of age. Precise risk …

Background The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to elicit T-cell-mediated
immune responses capable of providing complete or partial protection from HIV-1 …

Background. The development of an effective human immunodeficiency virus (HIV) vaccine
is a high global priority. Here, we report the safety, tolerability, and immunogenicity of a …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/…

Long COVID or post-acute sequelae of SARS-CoV-2 (PASC) is a clinical syndrome featuring
diverse symptoms that can persist for months following acute SARS-CoV-2 infection. The …

Ebola viruses represent a class of filoviruses that causes severe hemorrhagic fever with
high mortality. Recognized first in 1976 in the Democratic Republic of Congo, outbreaks …

Candidate HIV-1 vaccines currently being evaluated in clinical trials are designed to elicit
HIV-1-specific cellular immunity. Intracellular cytokine staining (ICS) assays allow sensitive, …